Promises and challenges of stem cell cargo therapy for bronchopulmonary dysplasia

Amanda Jacqueline Zayek,Binoy Shivanna

DOI: https://doi.org/10.1038/s41390-024-03631-4

IF: 3.953

2024-10-11

Pediatric Research

Abstract:Bronchopulmonary dysplasia (BPD) is a chronic lung disease that affects approximately 18,000 extremely low gestational age newborns annually in the United States, 1 and its incidence continues to rise with increasing survival rates of extremely preterm infants. Risk factors are multifactorial, spanning from prenatal to postnatal periods, and include male sex, intrauterine growth restriction, in-utero infections, mechanical ventilation, excessive oxygen exposure, and sepsis. Unfortunately, many of the postnatal risk factors contributing to BPD are part of essential life-sustaining treatments, such as mechanical ventilation and supplemental oxygen, making it challenging to mitigate the development of BPD while ensuring the survival of these vulnerable infants. Most infants who develop BPD are exposed to multiple risk factors. BPD has several phenotypes, including parenchymal disease, airway constriction, and vascular remodeling, with severe BPD infants having a combination of these phenotypes. Despite known histopathogenic hallmarks of BPD, like lung inflammation and interrupted lung development, effective preventive or curative interventions for BPD are limited. Caffeine and Vitamin A have modest effects in reducing BPD. 2 Dexamethasone, being a potent anti-inflammatory agent, is an appealing agent since BPD is predominantly an inflammatory lung disease. However, even dexamethasone has a modest effect in reducing BPD. 2 Additionally, its use is associated with significant non-pulmonary side effects. Further, animal studies indicate that dexamethasone can disrupt lung development, 3 raising concerns about its long-term safety in neonates. Given the limitations of existing therapies, novel approaches are urgently needed for treating BPD. One promising avenue is using stem cells or their acellular products, which target the core pathophysiological processes of BPD: lung inflammation and impaired repair mechanisms. While preclinical studies show potential, clinical translation faces safety and logistical hurdles. In this journal issue, Saneh et al. 4 comprehensively review the drawbacks of using stem cells, the benefits and challenges of using their secreted products instead with their mechanism of action, and directions to advance this acellular therapy to clinical practice in the context of BPD. Herein, we comment on the strengths and limitations of the Saneh et al. review article.

pediatrics